UCLM-802 is under clinical development by UTC Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UCLM-802’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UCLM-802 is under development for the treatment of mesothelin positive refractory solid tumor, mesothelioma, pancreatic cancer, biliary tract cancer, lung cancer, ovarian cancer, gastric cancer, bowel cancer, thymic carcinoma, esophageal cancer, breast cancer and endometrial cancer. It is administered through intravenous route and comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing mesothelin antigen (MSLN).
UTC Therapeutics overview
UTC Therapeutics is a biotechnology company providing T cell based treatments for cancers and other diseases. UTC Therapeutics is headquartered in Shanghai, China.
For a complete picture of UCLM-802’s drug-specific PTSR and LoA scores, buy the report here.